Search

everythinglearnresearchcommunity

for

Search:↓

Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.

Diphencyprone treatment increases CD8 lymphocytes in the scalp, which is associated with hair regrowth in alopecia areata patients.

Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.

Pioglitazone, Trimipramine, and Dimetindene may be repurposed to treat psoriasis.

Cronkhite-Canada syndrome is a rare disorder needing early recognition and treatment with immunosuppressive therapies and nutritional support to manage symptoms and prevent complications.

Chronic granulomatous disease may be linked to developing systemic lupus erythematosus.

The treatment was ineffective in humans.

Baricitinib at 2mg and 4mg doses improved work productivity and reduced costs for adults with atopic dermatitis.

New vitamin D3 forms need the vitamin D receptor to reduce fibrosis in human cells.

Researchers identified promising inhibitors for the BRD4 protein, including finasteride and amentoflavone.

New compounds called benzoquinolinones may treat conditions linked to excess DHT.

Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.

Cepharanthine and Trifluoperazine are effective against SARS-CoV-2.

PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.

Duloxetine, escitalopram, and finasteride may be effective against bacteria and fungi.

Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.

Hit15 shows promise as a COVID-19 treatment by reducing virus infection and inflammation.

Early diagnosis and treatment are crucial for CAPS, and Eculizumab can be effective.

JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.

Marine compounds from gorgonians and soft corals show promise for drug development, especially for chronic disorders.

Using CD123 to detect certain immune cells helps diagnose a type of hair loss condition.

RSPO1 could help create new diabetes treatments by increasing pancreatic β cells.

Topical metformin may improve hair regrowth in CCCA when added to standard treatments.

A woman's hair loss worsened after starting hepatitis C treatment due to immune changes in her hair follicles.

Cedrol may be an effective treatment for colorectal cancer.

A Chinese family had a child with a specific gene mutation causing vitamin D-resistant rickets, but the child improved with calcium and low-dose calcitriol.

New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.

Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.

Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.